Severe inflammation in the background liver cirrhosis correlates with the development of poorly differentiated HCC in HCV-associated liver cirrhosis

Internal Medicine

Volumn 51, Issue 18, 2012, Pages 2495-2501

  Tarao, Kazuo ^a   Miyakawa, Kaoru ^b   Miyagi, Yohei ^b   Ohkawa, Shinichi ^b   Morinaga, Soichiro ^b   Oshige, Kenji ^c   Yamamoto, Naoto ^b   Ueno, Makoto ^b   Kobayashi, Satoshi ^b   Kameda, Ryou ^b   Tamai, Setsuo ^b   Nakamura, Yoshiyasu ^b   Endo, Yuichi ^a   Kameda, Yoichi ^b   Okudaira, Masahiko ^d  

^a Tarao's Gastroenterological Clinic   (Japan)

^b KANAGAWA CANCER CENTER   (Japan)

^c YOKOHAMA NATIONAL UNIVERSITY   (Japan)

^d KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

HCV associated liver cirrhosis; Hepatcellular carcinoma; Hepatocarcinogenesis; Inflammation; Inflammatory index; Poorly differentiated HCC

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RISK; CELL DEGENERATION; FEMALE; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; INFLAMMATION; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NECROSIS; TUMOR PROMOTION;

AGED; CARCINOMA, HEPATOCELLULAR; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; INFLAMMATION; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NECROSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; WORLD HEALTH ORGANIZATION;

EID: 84867878310     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.51.7744     Document Type: Article

References (36)

1. Vasiliev JM, Moizhess TG. Tumorigenicity of sarcoma cells is enhanced by the local environment of implanted foreign body. Int J Cancer 30: 525-529, 1982
2. Hamada J, Takeichi N, Okuda F, et al. Progression of weakly malignant clone cells derived from rat mammary carcinoma by host cells reactive to plastic plates. Jpn J Cancer Res 83: 483-490,1992
3. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1: 431-435, 1981
4. Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO Classification of Tumours of the Digestive System. IARC press, Lyon,2010: 211-212
5. Kojiro M. Pathology of early hepatocellular carcinoma-Progression from early to advanced-. Hepat Gastroent 45: 1203-1205,1998
6. Sakamoto M, Hirohashi S, Shimosato Y. Early stage of multistep hepatocarcinogenesis: Adenomatous hyperplasia and early hepatocellular carcinoma. Human Pathol 22: 172-178, 1991
7. Kojiro M, Sugihara S, Nakashima O. Pathomorphologic characteristics of early hepatocellular carcinoma. In: Early Detection and Treatment of Liver Cancer. Gann monograph on cancer research No.38. Okuda K, Tobe T, Kitagawa T, Eds. Japan Scientific Societies Press, Tokyo, 1991: 29-38
8. Kondo F, Wada K, Nagato Y, et al. Biopsy diagnosis of welldifferentiated hepatocellular carcinoma based on new morphologic criteria. Hepatology 9: 751-755, 1989
9. Sugihara S, Nakashima O, Kojiro M, Majima Y, Takano M,Tanikawa K. The morphologic transition in hepatocellular carcinoma-A comparison of the individual histological features disclosed by ultrasound-guided fine-needle biopsy with at autopsy.Cancer 70: 1488-1492, 1992
10. Kennmochi K, Sugihara S, Kojiro M. Relationship of histologic grade of hepatocellular carcinoma (HCC) to tumor size, and demonstration of tumor cells of multiple different grade in single HCC. Liver 7: 18-26, 1987
11. Kumada T, Toyoda H, Tada T, et al. Evolution of hypointence hepatocellular nodules observed only in the hepatobiliary phase using Gd-EOB-DTPA enhanced magnetic resonance imaging. Am J Roent 197: 58-63, 2011
12. Okuda K. Space occupying lesions. In: Hepatobiliary Diseases. Okuda K, Ed. Blackwell Science, Philadelphia, 2000: 395
13. Tarao K, Rino Y, Ohkawa S, et al. Association between high serum alanine aminotransferase levels and more rapid development and higher rate of incidence of hepatocellular carcinoma in patients with hepatitis C virus-associated cirrhosis. Cancer 86: 589-595, 1999
14. Veldt BJ, Hansen BE, Ikeda K, et al. Long-term clinical outcome and effect of glycyrrhizin in 1093 chronic hepatitis C patients with non-response or relapse to interferon. Scand J Gastroenterol 41:1087-1094, 2006
15. Miyakawa K, Tarao K, Ohshige K, et al. High serum alanine aminotransferase levels for the first three successive years can predict very high incidence of hepatocellular carcinoma in patients with Child Stage A HCV-associated liver cirrhosis. Scand J Gastroenterol 44: 1340-1348, 2009
16. Tarao K, Ohkawa S, Shimizu A, et al. DNA synthesis activities of hepatocytes from noncancerous cirrhotic tissue and of hepatocellular carcinoma (HCC) cells from cancerous tissue can predict the survival of hepatectomized patients with HCC. Cancer 71: 3859-3863, 1993
17. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6: 24-37, 2006
18. Lin WW, Karin M. A cytokine-mediated link between innate immunity,inflammation, and cancer. J Clin Invest 117: 1175-1183,2007
19. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation,and cancer. Cell 140: 883-899, 2010
20. Haybaeck J, Zeller N, Wolf MJ, et al. A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell 16: 295-308, 2009
21. Park EJ, Lee JH, Yu GY, et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140: 197-208, 2010
22. Edmondson HA, Steiner PE. Primary carcinoma of the liver: A study of 100 cases among 48, 900 necropsies. Cancer 7: 462-503,1954
23. Zhou L, Rui JA, Ye DX, Wang SB, Chen SG, Qu Q. Edmondson-Steiner grading increases the predictive efficiency of TNM staging for long-term survival of patients with hepatocellular carcinoma after curative resection. Word J Surg 32: 1748-1756, 2008
24. Asahara T, Dohi K, Katayama K, et al. Factors affecting postoperative prognosis in the solitary-nodular type of hepatocellular carcinoma: experience of 132 cases in our institute. Hiroshima J Med Sci 47: 99-104, 1998
25. Shiffman ML, Hoffmann CM, Contos MJ, et al. A randomized,controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 117: 1164-1172, 1999
26. Arase Y, Ikeda K, Tsubota A, et al. Interferon therapy for 2 years or longer reduces the incidence of hepatocarcinogenesis in patients with chronic hepatitis C viral infection. Intervilorogy 47: 355-361, 2004
27. Arase Y, Ikeda K, Suzuki F, et al. Interferon-induced prolonged biochemical responce reduces hepatocarcinogenesis in hepatitis C virus infection. J Med Virol 79: 1485-1490, 2007
28. Nomura H, Kashiwagi Y, Hirano R, et al. Efficacy of low dose long-term interferon monotherapy in aged patients with chronic hepatitis C genotype 1 and its relation to alpha-fetorotein: A pilot study. Hepatology Res 37: 490-497, 2007
29. Lok AS, Everhart JE, Wright EC, et al. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology 140: 840-849, 2011
30. Bellentani S, Podda M, Tiribelli C, et al. Ursodiol in the longterm treatment of chronic hepatitis: a double-blind multicenter clinical trial. J Hepatol 19: 459-464, 1993
31. Omata M, Yoshida H, Toyota J, et al. A large-scale, multicenter, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C. Gut 56: 1747-1753, 2007
32. Suzuki H, Ohta Y, Takino T, Fujisawa K, Hirayama C. Effects of glycyrrhizin on biochemical tests in patients with chronic hepatitis-double blind trial. Asian Med J 26: 423-428, 1983
33. Arase Y, Ikeda K, Murashima N, et al. The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 79: 1494-1500,1997
34. Hirayama C, Okumura M, Tanikawa K, Yano M, Mizuta M, Ogawa N. A multicenter randomized control clinical trial of Shosaiko-to in chronic active hepatitis. Gastroenterol Jpn 24: 715-719,1989
35. Oka H, Yamamoto S, Kuroki T, et al. Prospective study of chemoprevention of hepatocellular carcinoma with Sho-saiko-to (TJ-9).Cancer 76: 743-749, 1995
36. Tarao K, Sakamoto Y, Ueno M, Miyakawa K, Ohkawa S. Juzentaihoto (TJ48) may be an important and effective anti-inflammatory agent for intractable cases of patients with HCVassociated chronic liver diseases. Kampo Med 61: 1-8, 2010 (inJapanese)